Main Uses and Applications

Discovisc is a specialized ophthalmic viscosurgical device (OVD) primarily utilized during anterior segment surgeries of the eye. It is most commonly employed during cataract extraction and the implantation of intraocular lenses. This solution is designed to maintain the depth of the anterior chamber and protect the delicate internal structures of the eye throughout various stages of the surgical procedure.

As a dispersive-cohesive OVD, it is formulated to offer the benefits of two different types of viscoelastic materials in a single injection. This dual-action nature allows it to serve multiple functions:

• Space Maintenance: It provides a stable environment for the surgeon to operate by maintaining the volume and shape of the anterior chamber.
• Tissue Protection: It creates a protective layer over the corneal endothelium, the innermost layer of cells in the cornea, which is sensitive to mechanical trauma and surgical manipulation.
• Tissue Manipulation: It assists in the gentle maneuvering of ocular tissues and helps in the controlled placement of the intraocular lens.

Clinical Benefits

The integration of both cohesive and dispersive properties into one solution provides several functional advantages during ophthalmic surgery:

Endothelial Cell Protection

One of the primary goals in eye surgery is to preserve the health of the corneal endothelial cells. These cells do not regenerate, and their loss can lead to permanent corneal clouding. The dispersive component of the solution adheres to the corneal wall, providing a durable buffer against surgical instruments, irrigation fluids, and ultrasound energy used during phacoemulsification.

Stability and Visibility

The cohesive characteristics of the solution ensure that it maintains the surgical space effectively under the high-flow conditions of modern surgery. This stability is crucial for ensuring the surgeon has a clear, unobstructed view of the surgical field and sufficient room to perform precise movements.

Efficient Removal

By combining properties, the solution is designed to remain in place when protection is needed but can be efficiently aspirated from the eye at the conclusion of the procedure. Thorough removal is an important step in managing the transition to the post-operative recovery phase.

Regulatory References

1. https://www.accessdata.fda.gov/cdrhdocs/pdf/P930014S126B.pdf

Who Can and Cannot Use Discovisc?

Discovisc is an Ophthalmic Viscosurgical Device (OVD), and its eligibility is determined by official regulatory documents based on patient population and local ocular status.

Absolute Contraindication

Use of Discovisc is formally contraindicated in patients with a known allergy or hypersensitivity to any of its components, which include Sodium Hyaluronate and Chondroitin Sulfate.

Population Eligibility and Restrictions

• Established Use: The device’s safety and effectiveness are established for adult and geriatric patients undergoing indicated anterior segment ophthalmic surgery.

• Pediatric Use: Use is not established for the pediatric population (patients under 18 years of age) due to a lack of data from regulatory trials.

• Restricted Conditions: Use is generally not recommended or is restricted in patients with specific high-risk ocular conditions, as these groups were excluded from pivotal studies. This includes patients with pre-existing glaucoma or ocular hypertension or those with a history of corneal pathology or severely low endothelial cell density. Specific systemic conditions like Proliferative Diabetic Retinopathy also define restricted eligibility.

• Organ Function: Eligibility rules related to severe hepatic or renal impairment are not specified in the official regulatory documents.

The official regulatory information for Discovisc is defined by its function as a sterile, non-systemic surgical aid. As an Ophthalmic Viscosurgical Device (OVD), a combination of Sodium Chondroitin Sulfate and Sodium Hyaluronate, it is administered locally via intraocular injection into the anterior chamber of the eye. This localized method of delivery means the product is not subject to the typical systemic pharmacokinetic (PK) and pharmacodynamic (PD) interactions associated with oral or intravenously administered medicines.

Interaction scope

Resulting interaction structure

The official regulatory documentation from government authorities, including the US Food and Drug Administration, does not contain a dedicated section detailing systemic drug-drug, drug-food, or substance interactions. Consequently, the labeling does not include warnings for contraindicated combinations, exposure-modifying effects, or specific population-dependent interaction considerations. The official interaction profile is defined by the absence of documented systemic interaction data, consistent with its non-systemic surgical use.

The mechanism of Discovisc is defined by its physicochemical and mechanical actions on the intraocular environment. The two main biopolymers, sodium hyaluronate and sodium chondroitin sulfate, exert a synergistic rheological effect targeting the aqueous humor and adjacent ocular tissue surfaces . The high viscosity and elasticity of the sodium hyaluronate component physically occupies space, establishing and maintaining a stable separation between delicate structures, which contributes to the reduction of mechanical contact between intraocular tissues. Separately, the sodium chondroitin sulfate component exhibits strong adhesion affinity for cellular surfaces, particularly the corneal endothelium. This adhesion creates a protective physical coating or barrier that restricts factors leading to acute cell loss during manipulation. The combination of cohesive space maintenance and dispersive tissue coating facilitates simultaneous structural separation and comprehensive surface coverage, promoting greater physical stability of intraocular structures.

How Discovisc is Used: Official Administration Guidelines

Discovisc is formally classified as an Ophthalmic Viscosurgical Device (OVD) and its use is strictly confined to the intraoperative context of anterior segment eye surgery. The instructions for use govern the technique, conditions, and required removal of the product.

Administration and Dosing

The approved method of delivery is intraocular injection (intracameral injection) directly into the anterior chamber of the eye. Unlike conventional medicines, there is no fixed dose or numerical dosage range specified in the official labeling. The amount of the Sodium Chondroitin Sulfate and Sodium Hyaluronate solution administered is the required amount determined intraoperatively by the surgeon. This quantity must be sufficient to maintain chamber volume and protect intraocular tissues during the procedure.

Discovisc is intended solely for single-event use, meaning it is administered once per surgical procedure. While it is applied as a single device, additional amounts may be injected during the operation to replace volume or maintain spatial stability, which classifies its use as as-needed intraoperative.

Preparation and Procedural Requirements

Prior to injection, the prefilled syringe must be allowed to reach room temperature if it has been refrigerated, and the solution must be verified to be clear. Administration must adhere to standard aseptic technique within the surgical environment. The product is temporary; standard protocols require that Discovisc be removed from the eye as completely as practical through thorough irrigation and aspiration at the end of the surgical procedure. The device and cannula are single-use only and must not be reused.

Research Evidence / Overview of Studies for Discovisc

Evidence for Use as a Surgical Aid in Cataract and Lens Surgery

Discovisc is formally classified as an Ophthalmic Viscosurgical Device (OVD) and was studied for its use during surgery involving the anterior segment of the eye, such as cataract extraction and intraocular lens (IOL) implantation. The evidence for this use includes Randomized Controlled Trials (RCTs). These studies typically compare Discovisc, which contains two components (chondroitin sulfate and sodium hyaluronate), to other OVD products that may contain only a single component.

These comparative studies and subsequent systematic reviews research examined the characteristics observed during the operation itself. Researchers explored the device's ability to maintain a stable workspace for the surgeon (anterior chamber maintenance) and how easily the surgeon could handle and remove the material when the procedure was complete. The evidence contributes to the broader evidence landscape by providing context on how this class of product functions when used as a necessary surgical aid.

Outcomes Studied in Clinical Trials

The research explored several key outcomes related to monitoring the status of the eye's internal structures during and after surgery. A central focus of the studies was the evaluation of Corneal Endothelial Cell Loss (ECL). Studies monitored changes in the cell density of the corneal endothelium (the delicate inner lining of the cornea), which is a measure of changes in tissue status. These measurements were taken at defined time intervals, such as three or six months post-surgery.

Research also examined patterns related to Intraocular Pressure (IOP), specifically looking at any temporary elevations or "spikes" that were measured in the immediate hours following surgery. Findings describe patterns observed in the studies related to IOP and other outcomes linked to physiological strain on the eye. Patient-reported outcomes describing perceived discomfort were observed in some studies.

Long-term Follow-up and Durability in Research

The typical research approach for this type of surgical device involves follow-up durations that were limited to the short- and intermediate-term. Studies monitored patients in the post-operative hours and continued to track outcomes like Endothelial Cell Loss and IOP up to three or six months. This means that long-term patterns of change are not fully established based on the current body of core comparative research.

Research in Specific Patient Groups

The study populations for the main comparative trials were primarily adults scheduled for routine, uneventful cataract surgery. These studies provide data for certain groups, but results apply only to the populations studied. Key comparative trials often featured exclusion criteria that meant patients with certain conditions marked by functional limitations (like very low pre-existing cell counts) were not included. This means that data for certain groups remain insufficient, and research exploring outcomes in patients with more complicated or non-routine surgical scenarios was observed in some studies but is not consistently available across the high-level evidence base.

Common questions about Discovisc (FAQ)

Q: Is Discovisc the same as other products used for joint pain?

No. Discovisc is formally classified in official documents as an Ophthalmic Viscosurgical Device (OVD) and is strictly used during intricate eye procedures in the anterior segment of the eye.

Its purpose is to function as a surgical aid to support and protect the eye's delicate internal tissues during the operation, not to treat joint pain or for use in the knee or other joints.

Q: Can Discovisc be used for joints other than the knee?

According to the official product information, Discovisc is an Ophthalmic Viscosurgical Device. The administration site is strictly via intraocular injection directly into the anterior chamber of the eye.

It is not intended for use in any joints of the body, and its regulatory clearance is specific to ophthalmic procedures.

Q: Is there a limit to how many times someone can receive Discovisc?

Official directions for use indicate that Discovisc is intended for single-event use, meaning it is administered once per surgical procedure.

The amount used is determined by the surgeon during the operation, and the material is completely removed at the end of the procedure.

Q: What should be avoided right after receiving a Discovisc injection?

Discovisc is used during the surgical procedure and is then removed. Warnings related to activity restrictions concern the post-operative period following the eye surgery itself.

Official regulatory guidance describes that caution is often exercised with activities that require good vision in dimly lit environments, such as driving at night.

Q: What is the difference between Discovisc and hyaluronic acid?

Discovisc is a combination product that features two key ingredients: Sodium Hyaluronate (a type of hyaluronic acid) and Sodium Chondroitin Sulfate.

The specialized formulation is designed to offer a balanced profile of both mechanical stability and tissue coating protection, differing from products that may contain only a single viscoelastic component.

Q: Is it normal to feel soreness at the injection site after Discovisc?

Official safety information lists documented adverse effects that occur in the immediate postoperative period and are classified as Eye disorders.

These localized adverse events include transient ocular inflammation (iritis/uveitis) and corneal edema, which may occur following the procedure.

Q: Why do some people need more than one Discovisc treatment?

Discovisc is used once per surgical procedure. The product's intended function is complete when the surgery concludes and the material is removed from the eye.

A person would only require subsequent 'treatments' if they needed to undergo a subsequent, separate anterior segment surgical procedure on the same or the other eye at a later date.

Q: Does Discovisc show up on a drug test?

Discovisc is formally defined as a non-systemic surgical aid. It is administered locally into the eye and is removed at the end of the procedure.

Since it does not enter the body's general circulation, it is not subject to the typical systemic pharmacokinetic interactions associated with orally or intravenously administered medicines.

Q: Are there different types or strengths of Discovisc?

According to official product information, Discovisc is supplied as a single standard product.

It is delivered as a 1 mL solution containing a specific concentration of both Sodium Chondroitin Sulfate (40 mg/mL) and Sodium Hyaluronate (17 mg/mL) in a prefilled syringe for single use.

Q: Has Discovisc been approved in countries outside the U.S.?

Regulatory filings for the product indicate that the manufacturer seeks authorization and conformity assessments in major international markets.

This suggests the product is regulated and available for use in various regions outside the U.S., including countries in the European Union and Japan.

Q: Is Discovisc considered a corticosteroid or a steroid?

No. Official documents classify Discovisc as an Ophthalmic Viscosurgical Device (OVD) and categorize it as an Ophthalmic Surgical Agent, which is a viscoelastic substance.

It is not an anti-inflammatory drug and is not considered a corticosteroid or a steroid.

Q: Can someone drive immediately after getting a Discovisc shot?

Discovisc is used during the eye surgery itself. Restrictions on driving after the procedure are related to the temporary vision effects of the surgery.

Official guidance indicates that caution is often exercised with activities that require good visibility, particularly in poor lighting or at night, following the ophthalmic procedure.

Q: Is Discovisc sourced from animals, or is it made synthetically?

Discovisc's two main components are derived from biological sources, though they differ in their specific origins.

The Sodium Hyaluronate component is produced via a microbial fermentation process, while the Chondroitin Sulfate component is derived from blue shark cartilage.

Q: Are there any specific activities that are restricted while using Discovisc?

The material is used and then removed during the surgery, so there are no restrictions on activity while the device is technically in use.

Any restrictions on post-operative activities, such as heavy lifting or specific positions, are general precautions related to the eye surgery itself and are determined by the treating physician.

Q: Can people with a history of heart problems use Discovisc?

Discovisc is administered locally into the eye and is a non-systemic surgical aid. Consequently, the official documentation does not contain warnings or contraindications related to systemic patient conditions like a history of heart problems.

Its use is determined by the patient's local ocular status and eligibility for the surgical procedure.

Q: Is Discovisc known to cause weight gain?

No. As a non-systemic surgical device, Discovisc is not subject to the systemic effects of traditional medicines.

The official safety profile focuses solely on localized adverse reactions classified under Eye disorders, and systemic effects like weight gain are not documented.

Q: Can Discovisc be used in patients who have previously had surgery on the joint?

Discovisc is an ophthalmic device used in the eye during surgery.

Previous non-ocular surgery on other parts of the body, such as a joint, is not listed as a contraindication in the official labeling for this product.

Q: Are there any warnings about Discovisc use and pregnancy or breastfeeding?

Official regulatory information states that there are no controlled data from studies in human pregnancy and no data on the excretion of the components into human milk.

Official regulatory information describes that use during pregnancy is assessed by a professional who must judge the expected benefit to outweigh the potential risk.

Q: Why do doctors use Discovisc instead of just giving a corticosteroid shot?

Discovisc and corticosteroid shots serve fundamentally different purposes. Discovisc is a mechanical surgical aid used to support, separate, and protect delicate tissues during the procedure.

A corticosteroid is a systemic drug used for its pharmacological anti-inflammatory properties and is not designed to provide the necessary mechanical support during eye surgery.

Q: Can Discovisc be used by patients with diabetes?

Official eligibility documents restrict the use of Discovisc for patients with specific high-risk ocular conditions, including Proliferative Diabetic Retinopathy.

The labeling does not specify restrictions for patients with uncomplicated diabetes mellitus alone, but the determination of eligibility is based on the patient's overall ocular status.

Q: How quickly can a person expect to feel the effects of Discovisc?

The device's functional effects—providing mechanical support, separation, and tissue protection—are immediate during the surgical procedure.

Any feeling of long-term improvement post-surgery is related to the overall outcome of the operation and is often monitored through research outcomes like reduced Corneal Endothelial Cell Loss.

Q: Do studies suggest Discovisc is effective for mild or severe joint issues?

Official research and clinical trial evidence for Discovisc is exclusively focused on its function as a surgical aid during anterior segment eye surgery, such as cataract extraction.

Discovisc has not been studied for or approved in the treatment of joint issues, regardless of severity.

The official storage conditions for Discovisc are strictly mandated to maintain the integrity of this sterile Ophthalmic Viscosurgical Device (OVD).

Mandatory Storage Conditions

• Store refrigerated between 2 C to 8 C (36 F to 46 F), and protect from freezing.
• Must be protected from light and stored out of the sight and reach of children.

Handling and Disposal

• The product is for single-use only; the contents must be used immediately after opening the sterile packaging and must not be reused.
• Use is permitted only if the sterile barrier is uncompromised and the glass syringe is undamaged.
• Any unused or expired syringes must be disposed of in accordance with local institutional and professional waste regulations.